Bristol Myers Squibb has announced that it has successfully completed the acquisition of RayzeBio, making the company a wholly-owned subsidiary of the group and resulting in its delisting from the Nasdaq Global Market.

The pharmaceutical company recalls that it had successfully completed its tender offer for RayzeBio at the end of last week, with approximately 53 million shares having been validly tendered, representing around 86% of RayzeBio's common shares.

"This transaction provides us with radiopharmaceutical therapeutics (RPT), one of the fastest-growing new treatment modalities for patients with solid tumors", emphasizes CEO Chris Boerner.

Copyright (c) 2024 All rights reserved.